Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3 Day Monotherapy in HCV Genotype-1 Infected Subjects With or Without Compensated Cirrhosis

Conference Reports for NATAP

65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014


Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3 Day Monotherapy in HCV Genotype-1 Infected Subjects With or Without Compensated Cirrhosis

	Reported by jules Levin AASLD Nov 7-11 2014 Boston Chih-Wei Lin, Wei Liu, Armen Asatryan, Andrew Campbell, Sandeep Dutta AbbVie Inc., North Chicago, Illinois, United States